Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spironolactone | 4 | 2012 | 36 | 1.240 |
Why?
|
| Aldosterone | 7 | 2012 | 66 | 0.890 |
Why?
|
| Kidney | 7 | 2012 | 363 | 0.710 |
Why?
|
| Nitric Oxide | 16 | 2019 | 381 | 0.670 |
Why?
|
| Hypertension | 10 | 2007 | 817 | 0.640 |
Why?
|
| Blood Pressure | 19 | 2012 | 658 | 0.560 |
Why?
|
| Epoprostenol | 11 | 2012 | 28 | 0.490 |
Why?
|
| Rats, Inbred Dahl | 9 | 2012 | 33 | 0.420 |
Why?
|
| Rats | 21 | 2012 | 3701 | 0.410 |
Why?
|
| Sodium Chloride, Dietary | 3 | 2011 | 39 | 0.400 |
Why?
|
| Hypotension | 2 | 2003 | 24 | 0.390 |
Why?
|
| Cyclooxygenase 1 | 1 | 2012 | 13 | 0.370 |
Why?
|
| Losartan | 3 | 2007 | 35 | 0.370 |
Why?
|
| Heart Rate | 14 | 2012 | 260 | 0.370 |
Why?
|
| Simvastatin | 3 | 2007 | 28 | 0.360 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 106 | 0.360 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 180 | 0.300 |
Why?
|
| Antioxidants | 2 | 2019 | 439 | 0.300 |
Why?
|
| Membrane Proteins | 1 | 2012 | 548 | 0.290 |
Why?
|
| Endothelium, Vascular | 3 | 2007 | 261 | 0.280 |
Why?
|
| Angiotensin II | 7 | 2007 | 103 | 0.280 |
Why?
|
| Hindlimb Suspension | 5 | 2003 | 16 | 0.270 |
Why?
|
| Weightlessness Simulation | 4 | 2003 | 26 | 0.260 |
Why?
|
| Thromboxane A2 | 7 | 2007 | 20 | 0.250 |
Why?
|
| Enalapril | 1 | 2006 | 7 | 0.240 |
Why?
|
| Cyclic N-Oxides | 1 | 2006 | 19 | 0.240 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2006 | 78 | 0.240 |
Why?
|
| Nitric Oxide Synthase | 2 | 2003 | 134 | 0.230 |
Why?
|
| Enzyme Inhibitors | 4 | 2003 | 457 | 0.220 |
Why?
|
| Prostaglandins | 3 | 2005 | 28 | 0.220 |
Why?
|
| Animals | 21 | 2012 | 16694 | 0.210 |
Why?
|
| Aorta | 5 | 2005 | 197 | 0.210 |
Why?
|
| Oxidative Stress | 7 | 2019 | 990 | 0.210 |
Why?
|
| Thiazines | 1 | 2003 | 4 | 0.200 |
Why?
|
| Dinoprostone | 4 | 2012 | 69 | 0.190 |
Why?
|
| Dinoprost | 3 | 2011 | 22 | 0.190 |
Why?
|
| Blotting, Western | 3 | 2019 | 884 | 0.180 |
Why?
|
| Acetophenones | 2 | 2012 | 10 | 0.180 |
Why?
|
| Systole | 2 | 2012 | 67 | 0.180 |
Why?
|
| Angiotensins | 1 | 2001 | 10 | 0.180 |
Why?
|
| Diet | 1 | 2007 | 810 | 0.170 |
Why?
|
| Male | 19 | 2012 | 22745 | 0.160 |
Why?
|
| Sex Characteristics | 2 | 2001 | 253 | 0.160 |
Why?
|
| Vasoconstriction | 2 | 2005 | 40 | 0.160 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2004 | 1737 | 0.160 |
Why?
|
| Body Weight | 6 | 2011 | 428 | 0.160 |
Why?
|
| Vasoconstrictor Agents | 3 | 2012 | 41 | 0.150 |
Why?
|
| Trabecular Meshwork | 1 | 2019 | 10 | 0.150 |
Why?
|
| Calcium Channel Agonists | 1 | 1998 | 3 | 0.150 |
Why?
|
| Vasopressins | 1 | 1998 | 12 | 0.150 |
Why?
|
| Hypotension, Orthostatic | 4 | 2002 | 6 | 0.150 |
Why?
|
| Calcium Channel Blockers | 1 | 1998 | 57 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 147 | 0.140 |
Why?
|
| Glaucoma | 1 | 2019 | 98 | 0.140 |
Why?
|
| Calcium | 1 | 1998 | 487 | 0.120 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 3 | 2003 | 5 | 0.110 |
Why?
|
| Sodium Chloride | 2 | 2006 | 54 | 0.100 |
Why?
|
| Glutathione | 5 | 2005 | 170 | 0.090 |
Why?
|
| Superoxides | 3 | 2007 | 57 | 0.090 |
Why?
|
| Salts | 2 | 2002 | 18 | 0.090 |
Why?
|
| Antihypertensive Agents | 2 | 2004 | 285 | 0.090 |
Why?
|
| Urinalysis | 1 | 2011 | 34 | 0.090 |
Why?
|
| Weightlessness Countermeasures | 2 | 2001 | 2 | 0.080 |
Why?
|
| Proteinuria | 1 | 2011 | 55 | 0.080 |
Why?
|
| Baroreflex | 4 | 2003 | 10 | 0.080 |
Why?
|
| Sodium | 1 | 2011 | 101 | 0.080 |
Why?
|
| Protein Subunits | 1 | 2011 | 93 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2019 | 128 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2007 | 37 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 928 | 0.080 |
Why?
|
| Rats, Inbred SHR | 2 | 2007 | 30 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2007 | 89 | 0.080 |
Why?
|
| Thromboxane B2 | 3 | 2004 | 9 | 0.080 |
Why?
|
| Vasodilator Agents | 3 | 2005 | 55 | 0.070 |
Why?
|
| Peptide Fragments | 2 | 2002 | 301 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 233 | 0.070 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2007 | 10 | 0.070 |
Why?
|
| Sodium, Dietary | 1 | 2007 | 22 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2006 | 1582 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2007 | 117 | 0.060 |
Why?
|
| Spin Labels | 1 | 2006 | 12 | 0.060 |
Why?
|
| Nitroprusside | 2 | 2003 | 14 | 0.060 |
Why?
|
| Phenylephrine | 2 | 2003 | 32 | 0.060 |
Why?
|
| Lipids | 1 | 2007 | 256 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2006 | 189 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2006 | 1554 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 1066 | 0.060 |
Why?
|
| Amlodipine | 1 | 2004 | 20 | 0.050 |
Why?
|
| Space Simulation | 1 | 2003 | 1 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2003 | 31 | 0.050 |
Why?
|
| Carotid Arteries | 1 | 2003 | 35 | 0.050 |
Why?
|
| Weightlessness | 1 | 2003 | 27 | 0.050 |
Why?
|
| Blood Vessels | 1 | 2003 | 36 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2002 | 1111 | 0.050 |
Why?
|
| Time Factors | 3 | 2002 | 1845 | 0.050 |
Why?
|
| Plant Oils | 1 | 2002 | 20 | 0.050 |
Why?
|
| Prostaglandins H | 1 | 2002 | 1 | 0.050 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2002 | 11 | 0.050 |
Why?
|
| Angiotensin I | 1 | 2002 | 5 | 0.050 |
Why?
|
| Indomethacin | 1 | 2001 | 26 | 0.050 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2001 | 36 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2001 | 34 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2001 | 87 | 0.040 |
Why?
|
| E-Selectin | 1 | 2019 | 23 | 0.040 |
Why?
|
| Interleukin-1alpha | 1 | 2019 | 18 | 0.040 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 1998 | 2 | 0.040 |
Why?
|
| Diltiazem | 1 | 1998 | 4 | 0.040 |
Why?
|
| Cyclic GMP | 3 | 2004 | 55 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2019 | 74 | 0.040 |
Why?
|
| Potassium Chloride | 1 | 1998 | 26 | 0.040 |
Why?
|
| Buthionine Sulfoximine | 3 | 2003 | 13 | 0.040 |
Why?
|
| Female | 4 | 2003 | 23980 | 0.030 |
Why?
|
| Sex Factors | 1 | 2001 | 1004 | 0.030 |
Why?
|
| Mesenteric Arteries | 2 | 2005 | 20 | 0.030 |
Why?
|
| Organ Size | 2 | 2005 | 167 | 0.030 |
Why?
|
| Cyclic AMP | 2 | 2004 | 135 | 0.020 |
Why?
|
| Myocardium | 2 | 2005 | 250 | 0.020 |
Why?
|
| Head-Down Tilt | 2 | 2002 | 4 | 0.020 |
Why?
|
| Humans | 3 | 2019 | 42113 | 0.020 |
Why?
|
| Acetylcholine | 1 | 2005 | 76 | 0.010 |
Why?
|
| Glutathione Disulfide | 1 | 2005 | 8 | 0.010 |
Why?
|
| Microcirculation | 1 | 2005 | 40 | 0.010 |
Why?
|
| Renin-Angiotensin System | 1 | 2005 | 44 | 0.010 |
Why?
|
| Second Messenger Systems | 1 | 2004 | 14 | 0.010 |
Why?
|
| Heart | 1 | 2005 | 181 | 0.010 |
Why?
|
| F2-Isoprostanes | 1 | 2003 | 20 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2003 | 97 | 0.010 |
Why?
|
| Isoprostanes | 1 | 2002 | 14 | 0.010 |
Why?
|
| Computer Graphics | 1 | 2002 | 19 | 0.010 |
Why?
|
| Cardiovascular Deconditioning | 1 | 2002 | 2 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 111 | 0.010 |
Why?
|
| Eicosanoids | 1 | 2002 | 6 | 0.010 |
Why?
|
| Space Flight | 1 | 2001 | 18 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 99 | 0.010 |
Why?
|
| Blood Circulation | 1 | 2001 | 3 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2002 | 77 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2001 | 36 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2001 | 110 | 0.010 |
Why?
|
| Vasodilation | 1 | 2001 | 63 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 2001 | 198 | 0.010 |
Why?
|